1 / 15

Antibacterial Drugs Market Expected to Reach USD 38.9 Billio

According to a new market report published by Transparency Market Research “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the global antibacterial drugs market was valued at USD 43.9 billion in 2014 and is estimated to reach USD 38.8 billion by 2023 at a CAGR of (1.3%) from 2015 to 2023.

Alinajohn
Télécharger la présentation

Antibacterial Drugs Market Expected to Reach USD 38.9 Billio

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 Published Date 2015-07-01 150 Page Report Request Sample Buy Now Press Release Antibacterial Drugs Market Expected to Reach USD 38.9 Billion Globally in 2023 Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Antibacterial Drugs Market REPORT DESCRIPTION According to a new market report published by Transparency Market Research “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the global antibacterial drugs market was valued at USD 43.9 billion in 2014 and is estimated to reach USD 38.8 billion by 2023 at a CAGR of (1.3%) from 2015 to 2023. Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 by Alexander Fleming and has evolved into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases, where substitute methodologies are available. This property has made antibacterial drugs an indispensable part of human health care. Over the period, the bacteria have genetically mutated giving rise to multi-drug resistant (MDR) variants. The prevalence of MDR bacterial infections is also on a hike; according to World Health Organization (WHO) in 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB. Browse the Antibacterial Drugs Market Report at http://www.transparencymarketresearch.com/antibacterial-drugs- market.html Antibacterial drugs are classified into eight major classes, namely, aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. The B-lactams class was the largest segment of the global antibacterial drugs market in 2014, with 58% share. Quinolones was identified as the second largest class, which held a share of 17% of the global antibacterial drugs market in 2014 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones administration. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period. The key drugs in pipeline have been identified for this market (currently in phase III clinical trials) and sales forecast has been provided for those expected to be launched during the forecast period (2015 to 2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & 2 Transparency Market Research

  3. Antibacterial Drugs Market Co.) and others. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, future commercialization of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the leading player in the antibacterial drugs market. Major end-users for antibacterial drugs include hospitals, private clinics, physicians and patients. Browse the full Antibacterial Drugs Market (By Class- Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous Browse the Press Release:http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm The global antibacterial drugs market has been segmented as below: Global Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD Million) Aminoglycosides B-Lactams Tetracyclines Sulfonamides Quinolones/Fluoroquinolones Macrolides Phenicols Miscellaneous Antibacterials Pipeline Analysis of Antibacterial Drugs Market 3 Transparency Market Research

  4. Antibacterial Drugs Market Actoxumab/Aezlotoxumab, (MK-3415A) Surotomycin (MK-4261) Arikace Cadazolid Ciprofloxacin/Fluocinolone Acetonide Zempia (E-101) Carbavance (meropenem/RPX7009) Ozenoxacin RHB-105 SPL7013 Delafloxacin Solithromycin (CEM-101) Eravacycline Delamanid SYM-1219 Omadacycline (PTK-0796) Plazomycin Global Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million) North America U.S. Canada Europe U.K. Germany 4 Transparency Market Research

  5. Antibacterial Drugs Market Rest of Europe Asia-Pacific China Japan Rest of Asia Pacific Latin America Brazil Rest of Latin America Rest of the World (RoW) Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567 Table of Contents Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Sources 1.3.1.1 Secondary Research 1.3.1.2 Primary Research Chapter 2 Executive Summary 2.1 Market Snapshot: Global Antibacterial Drugs Market 2.2 Comparative Analysis: Global Antibacterial Drugs Market, by Geography, 2014 and 2022 (Value %) 5 Transparency Market Research

  6. Antibacterial Drugs Market Chapter 3 Market Overview 3.1 Introduction to Antibacterial Drugs 3.2 Drivers 3.2.1 High prevalence of infectious diseases 3.2.2 Government support in research and development of antibacterial drugs 3.3 Restraints 3.3.1 Upcoming patent expirations and subsequent launch of generics 3.3.2 Rise in drug resistant species 3.4 Opportunities 3.4.1 Product differentiation through technological innovation, use of monoclonal antibodies (mAbs), combination products, new formulations and indications 3.5 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2013 - 2023 (USD Million) 4.1 Overview 4.1.1 Global Antibacterial Drugs Market Revenue, by Class, 2013 – 2022 (USD Million) 4.2 Aminoglycosides 4.2.1 Global Aminoglycosides Market Revenue, 2013 – 2022 (USD Million) 4.3 B-Lactams 4.3.1 Global β-Lactams Market Revenue, 2013 – 2022 (USD Million) 4.3.2 Penicillins 4.3.3 Carbapenems 4.3.4 Cephalosporins 6 Transparency Market Research

  7. Antibacterial Drugs Market 4.4 Tetracyclines 4.4.1 Global Tetracyclines Market Revenue, 2013 – 2022(USD Million) 4.5 Sulfonamides 4.5.1 Global Sulfonamides Market Revenue, 2013 – 2022 (USD Million) 4.6 Quinolones/Fluoroquinolones 4.6.1 Global Quinolones/Fluoroquinolones Market Revenue, 2013 – 2022(USD Million) 4.7 Macrolides 4.7.1 Global Macrolides Market Revenue, 2013 – 2022(USD Million) 4.8 Phenicols 4.8.1 Global Phenicols Market Revenue, 2013 – 2022(USD Million) 4.9 Miscellaneous Anti-bacterial 4.9.1 Global Miscellaneous Antibacterial Market Revenue, 2013 – 2022(USD Million) Chapter 5 Global Antibacterial Drug Pipeline Analysis 5.1 Introduction 5.2 Actoxumab/bezlotoxumab (MK-3415A) 5.2.1 Actoxumab/Bezlotoxumab (MK-3415A) Market Revenue, 2016 – 2022 (USD Million) 5.3 Surotomycin (MK-4261) 5.3.1 Surotomycin (MK-4261) Market Revenue, 2016 – 2022 (USD Million) 5.4 Arikace 5.4.1 Arikace Market Revenue, 2017 – 2022 (USD Million) 5.5 Cadazolid 5.5.1 Cadazolid Market Revenue, 2016 – 2022 (USD Million) 5.6 Ciprofloxacin/Fluocinolone Acetonide 7 Transparency Market Research

  8. Antibacterial Drugs Market 5.6.1 Ciprofloxacin/Fluocinolone Acetonide Market Revenue, 2016 – 2022 (USD Million) 5.7 Zempia (E-101) 5.7.1 Zempia (E-101) Market Revenue, 2017 – 2022 (USD Million) 5.8 Carbavance (meropenem/RPX7009) 5.8.1 Carbavance Market Revenue, 2017 – 2022 (USD Million) 5.9 Ozenoxacin 5.9.1 Ozenoxacin Market Revenue, 2016 – 2022 (USD Million) 5.10 RHB-105 5.10.1 RHB-105 Market Revenue, 2016 – 2022 (USD Million) 5.11 SPL7013 5.11.1 SPL7013 Market Revenue, 2016 – 2022 (USD Million) 5.12 SYM-1219 5.12.1 SYM-1219 Market Revenue, 2017 – 2022 (USD Million) 5.13 Delafloxacin 5.13.1 Delafloxacin Market Revenue, 2016 – 2022 (USD Million) 5.14 Solithromycin 5.14.1 Solithromycin Market Revenue, 2016 – 2022 (USD Million) 5.15 Eravacycline 5.15.1 Eravacycline Market Revenue, 2016 – 2022 (USD Million) 5.16 Delamanid 5.16.1 Delamanid Market Revenue, 2017 – 2022 (USD Million) 5.17 Omadacycline (PTK-0796) 5.17.1 Omadacycline Market Revenue, 2017 – 2022 (USD Million) 5.18 Plazomycin 8 Transparency Market Research

  9. Antibacterial Drugs Market 5.18.1 Plazomicin Market Revennue, 2017 – 2022 (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million) 6.1 Overview 6.1.1 Global Antibacterial Drugs Market Revenue, by Geography, 2013 – 2022 (USD Million) 6.2 North America 6.2.1 North America Antibacterial Drugs Market Revenue, 2013 – 2022 (USD Million) 6.3 Europe 6.3.1 Europe Antibacterial Drugs Market Revenue, 2013 – 2022 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million) 6.5 Latin America 6.5.1 Latin America Antibacterial Drugs Market Revenue, 2013 – 2022 (USD Million) 6.6 Rest of the World 6.6.1 Rest of the World (RoW) Antibacterial Drugs Market Revenue, 2013 – 2022 (USD Million) Chapter 7 Recommendations 7.1 Development of combination products 7.2 Rising demand for generic antibacterial drugs from developing anddeveloped countries is potential market for new entrants and generic manufacturers 7.3 Strategic collaborations with small biotechnology and research companies 7.4 Focusing on Gram-negative bacteria Chapter 8 Company Profiles 9 Transparency Market Research

  10. Antibacterial Drugs Market 8.1 AstraZeneca plc 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.5 Recent Developments 8.2 Allergan plc (Actavis Plc) 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Mergers and Acquisitions 8.2.5 Recent Developments 8.3 Bayer AG 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.5 Recent Developments 8.4 Bristol-Myers Squibb Company 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.5 Recent Developments 10 Transparency Market Research

  11. Antibacterial Drugs Market 8.5 Eli Lilly and Company 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 GlaxoSmithKline plc 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Johnson & Johnson 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.7.5 Recent Developments 8.8 Merck & Co., Inc. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies 8.8.5 Recent Developments 11 Transparency Market Research

  12. Antibacterial Drugs Market 8.9 Novartis AG 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.9.5 Recent Developments 8.10 Pfizer, Inc. 8.10.1 Company Overview 8.10.2 Financial Overview 8.10.3 Product Portfolio 8.10.4 Business Strategies 8.10.5 Recent Developments 8.11 Sanofi 8.11.1 Company Overview 8.11.2 Financial Overview 8.11.3 Product Portfolio 8.11.4 Business Strategies 8.11.5 Recent Developments List of Figures FIG. 1 Antibacterial Drugs: Market Segmentation FIG. 2 Global Antibacterial Drugs Market Revenue, by Class, 2012 (USD Million) FIG. 3 Comparative Analysis: Global Antibacterial Drugs Market, by Geography, 2014 and 2022 (Value %) FIG. 4 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography 12 Transparency Market Research

  13. Antibacterial Drugs Market FIG. 5 Global Aminoglycosides Market Revenue, 2013 – 2022 (USD Million) FIG. 6 Global β-Lactams Market Revenue, 2013 – 2022 (USD Million) FIG. 7 Global Tetracyclines Market Revenue, 2013 – 2022(USD Million) FIG. 8 Global Sulfonamides Market Revenue, 2013 – 2022 (USD Million) FIG. 9 Global Quinolones/Fluoroquinolones Market Revenue, 2013 – 2022(USD Million) FIG. 10 Global Macrolides Market Revenue, 2013 – 2022(USD Million) FIG. 11 Global Phenicols Market Revenue, 2013 – 2022(USD Million) FIG. 12 Global Miscellaneous Antibacterial Market Revenue, 2013 – 2022(USD Million) FIG. 13 Actoxumab/Bezlotoxumab (MK-3415A) Market Revenue, 2016 – 2022 (USD Million) FIG. 14 Surotomycin (MK-4261) Market Revenue, 2016 – 2022 (USD Million) FIG. 15 Arikace Market Revenue, 2017 – 2022 (USD Million) FIG. 16 Cadazolid Market Revenue, 2016 – 2022 (USD Million) FIG. 17 Ciprofloxacin/Fluocinolone Acetonide Market Revenue, 2016 – 2022 (USD Million) FIG. 18 Zempia (E-101) Market Revenue, 2017 – 2022 (USD Million) FIG. 19 Carbavance Market Revenue, 2017 – 2022 (USD Million) FIG. 20 Ozenoxacin Market Revenue, 2016 – 2022 (USD Million) FIG. 21 RHB-105 Market Revenue, 2016 – 2022 (USD Million) FIG. 22 SPL7013 Market Revenue, 2016 – 2022 (USD Million) FIG. 23 SYM-1219 Market Revenue, 2017 – 2022 (USD Million) FIG. 24 Delafloxacin Market Revenue, 2016 – 2022 (USD Million) FIG. 25 Solithromycin Market Revenue, 2016 – 2022 (USD Million) FIG. 26 Eravacycline Market Revenue, 2016 – 2022 (USD Million) FIG. 27 Delamanid Market Revenue, 2017 – 2022 (USD Million) FIG. 28 Omadacycline Market Revenue, 2017 – 2022 (USD Million) 13 Transparency Market Research

  14. Antibacterial Drugs Market FIG. 29 Plazomicin Market Revennue, 2017 – 2022 (USD Million) FIG. 30 AstraZeneca plc: Annual Revenue, 2012 – 2014 (USD Million) FIG. 31 Allergan plc: Annual Revenue, 2012 – 2014 (USD Million) FIG. 32 Bayer AG: Annual Revenue, 2012 – 2014 (USD Million) FIG. 33 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (USD Million) FIG. 34 Eli Lilly and Company: Annual Revenue, 2012 – 2014 (USD Million) FIG. 35 GlaxoSmithKline plc: Annual Revenue, 2012 – 2014 (USD Million) FIG. 36 Johnson & Johnson (Pharmaceuticals): Annual Revenue, 2012 – 2014 (USD Million) FIG. 37 Merck & Co., Inc.: Annual Revenue, 2012– 2014 (USD Million) FIG. 38 Novartis AG: Annual Revenue, 2012 – 2014 (USD Million) FIG. 39 Pfizer, Inc.: Annual Revenue, 2012 – 2014 (USD Million) FIG. 40 Sanofi: Annual Revenue, 2012 – 2014 (USD Million) List of Tables TABLE 1 Market Snapshot: Global Antibacterial Drugs Market TABLE 2 Global Antibacterial Drugs Market Revenue, by Class, 2013 – 2022 (USD Million) TABLE 3 Antibacterial Drugs Pipeline: Phase III candidates TABLE 4 Global Antibacterial Drugs Market Revenue, by Geography, 2013 – 2022 (USD Million) TABLE 5 North America Antibacterial Drugs Market Revenue, by Country, 2013 – 2022 (USD Million) TABLE 6 Europe Antibacterial Drugs Market Revenue, by Country, 2013 – 2022 (USD Million) TABLE 7 Asia Pacific Antibacterial Drugs Market Revenue, by Country, 2013 – 2022 (USD Million) TABLE 8 Latin America Antibacterial Drugs Market Revenue, by Country, 2013 – 2022 (USD Million) TABLE 9 Rest of the World Antibacterial Drugs Market Revenue, by Country, 2013 – 2022 (USD Million) About Us 14 Transparency Market Research

  15. Antibacterial Drugs Market Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward- looking insight for thousands of decision makers. We are privileged with a highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Mr.Nachiket 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ 15 Transparency Market Research

More Related